Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemiaOthman Al‐Sawaf, Kirsten Fischer, Alex Kotak et al.|Nature Communications|2023Cited by 94
Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemiaOthman Al‐Sawaf, Kirsten Fischer, Can Zhang et al.|Nature Communications|2023Cited by 3
Response to Subsequent Novel Therapies and Time to Second Progression-Free Survival Event in the MURANO Trial in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with Fixed-Dose Venetoclax Plus RituximabRosemary Harrup, John F. Seymour, Arnon P. Kater et al.|Blood|2023Cited by 0